Beige and Brown Fat: Basic Biology and Novel Therapeutics

Organizer(s): Bruce M. Spiegelman and Sven Enerbäck

Sponsored by AstraZeneca

For important information on the coronavirus, please click here

Summary of Meeting:

The epidemic of obesity and diabetes has become a world-wide health risk. These metabolic disorders are a direct threat to the health and economic well-being of many nations. Unfortunately, education about diet and exercise are not sufficient to meet this emergency and new therapies are badly needed. Brown fat has emerged as one of the few genuinely new approaches to these problems. Brown fat exists in most or all adult humans and can dissipate caloric energy and improve both obesity and diabetes in experimental animals. This meeting will focus on new pathways controlling brown fat development and thermogenesis. We will delve into the types of brown fat cells, beige, classical brown and others. We will also put a special emphasis on emerging approaches, both biological and chemical, that can manipulate these cells for therapeutic purposes. It is our hope and belief that this meeting can nucleate expanded efforts in both academia and pharma to explore this promising research area. There has not been a Keystone Symposia conference dedicated to brown fat. While there has been a session here and there at the Obesity meeting, the science and the biomedical needs warrant this new and focused conference. Of course, this will also bridge the Obesity and Diabetes communities, and lead to pharma/academic collaborations.

Scholarship Deadline: December 16 2014

Discounted Abstract Deadline: December 16 2014

Abstract Deadline: January 15 2015

Discounted Registration Deadline: February 18 2015

Abstacts when book is in proofing process

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Ember Therapeutics

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1R13DK104499-01
Funding for this conference was made possible (in part) by 1 R13 DK104499-01 from NIDDK. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations